Versant Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History
Bought
Maintained
Sold
Other funds holding ADPT
Versant Capital Management's ADPT Position: Q3 2026 in Review
Versant Capital Management increased its Adaptive Biotechnologies (ADPT) stake by 8.1% in Q3 2026, buying an estimated $982 and bringing the position to 534 shares worth $15.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2083.
Versant Capital Management first reported a position in ADPT in Q2 2023 and has held it in 10 quarters since. 334 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.
- Versant Capital Management held 534 shares of Adaptive Biotechnologies worth $15.4K as of Q3 2026.
- Versant Capital Management bought 40 Adaptive Biotechnologies shares in Q3 2026, an estimated $982.
- Adaptive Biotechnologies made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2083 holding.
- Versant Capital Management first reported a position in Adaptive Biotechnologies in Q2 2023 and has held it in 10 quarters since.
- 334 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.
Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.